Jnana Therapeutics Inc.

AbbVie is paying $1.4bn in cash for privately held Aliada Therapeutics and its sole clinical candidate – but if ALIA-1758 proves to be a best-in-class disease-modifying therapy for Alzheimer’s disease

Merger-and-acquisition activity in the biopharmaceutical sector fell off sharply during the third quarter, a second consecutive quarter of decline after the busy and high-spending Q4 2023 and Q1 2024,

Pharma companies are constantly struggling to replace products that face loss of exclusivity (LoE) with a promising pipeline, and Otsuka Pharmaceutical Co. Ltd. ’s acquisition deal for US biotech Jn

Otsuka Pharmaceutical Co. Ltd. is paying up to $1.3bn for private US-based drug discovery specialist Jnana Therapeutics Inc. , in a deal that will give the Japanese major access to platform technolo